Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ARR, DB, WB
Citations:
8
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
mol wt
antigen 80 kDa
species reactivity
rat
concentration
0.5 mg/mL
technique(s)
dot blot: 1:1,000, microarray: suitable, western blot: 1:8,000 using rat brain extract
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
rat ... Prkcb(25023)
General description
Protein Kinase C (PKC, 76-93 kD) is a family of Ser/Thr specific protein kinases that perform key functions in numerous signalling pathways, in biological systems, through their various isoforms. The conventional PKC isoforms (cPKC) are PKC-α, β1, β2 and γ; activated by phosphatidylserine, calcium or phorbol esters. Proteolysis of PKC in vivo is thought to be mediated by calpains I and II. Calpains cleave PKC in the V3 hinge region to produce two distinct fragments, one comprising the N-terminal regulatory domain (30 kD) and the other fragment containing the C-terminal kinase domain (50 kD) that is catalytically active. Multiple functions such as, cellular and vascular regulations, angiogenesis, cell growth, apoptosis, changes in basement membrane thickness, extracellular matrix organisation, MAPK signalling, are attributed to PKC isoforms. These varied functions implicate PKC isoforms in cardiac hypertrophies and diabetic nephropathy and cardiovascular complications.
Anti-Protein Kinase C β2 antibody specifically recognises PKC β2 (80 kDa).
Anti-Protein Kinase C β2 antibody specifically recognises PKC β2 (80 kDa).
Immunogen
synthetic peptide corresponding to the C-terminal region of PKC β2 (660-673).
Application
Anti-Protein Kinase C β2 antibody may be used for detection by immunoblotting at a working dilution of 1:8000 using rat brain extract. It may be used in dat blot at a working dilution of 1:1000. It is suitable for protein microarray.
Biochem/physiol Actions
In immunoblotting, the product reacts with PKC β2 (80 kDa) using rat brain extract.
Physical form
Supplied in 0.01 M phosphate buffered saline, pH 7.4, containing 1% BSA and 15 mM sodium azide.
Preparation Note
Purified by affinity chromatography using immobilized PKC β2 peptide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Sara Abu-Ghanem et al.
Cancer biology & therapy, 6(9), 1375-1380 (2007-09-06)
The Hodgkin-Reed-Sternberg (HRS) malignant cells in Hodgkin's lymphoma (HL) originate from germinal center B lymphocytes that did not undergo apoptosis. Protein Kinase C (PKC), a family of serine/threonine kinases, plays a crucial role in signal transduction modulating cell growth, differentiation
Weiqin Yin et al.
Journal of diabetes investigation, 10(3), 613-625 (2018-10-12)
Blockade or reversal the progression of diabetic nephropathy is a clinical challenge. The aim of the present study was to examine whether recombinant human glucagon-like peptide-1 (rhGLP-1) has an effect on alleviating urinary protein and urinary albumin levels in diabetic
Domain interactions in protein kinase C.
C J Pears et al.
Journal of cell science, 100 ( Pt 4), 683-686 (1991-12-01)
S Budhiraja et al.
Fundamental & clinical pharmacology, 22(3), 231-240 (2008-05-20)
Diabetic nephropathy (DN) has emerged as the major causative pathology in patients entering end-stage renal disease (ESRD) worldwide and it is responsible for 30-40% of all ESRD cases. Treatments for DN are centered on control of hyperglycemia and blood pressure
Julio Cesar Batista Ferreira et al.
Journal of molecular and cellular cardiology, 51(4), 479-484 (2010-11-03)
Cardiac hypertrophy is a complex adaptive response to mechanical and neurohumoral stimuli and under continual stressor, it contributes to maladaptive responses, heart failure and death. Protein kinase C (PKC) and several other kinases play a role in the maladaptative cardiac
Related Content
Datasheet
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service